What You Need to Know About Bio-Techne Corporation's Q2 Earnings
Bio-Techne Corporation's fiscal Q2 earnings report was released on Friday, November 06. Let's dive in to see if (TECH) missed or beat analyst's expectations.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Michael Rose
Jenna Brashear
Omar Beirat
| Share Statistics | TECH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,436.2 | $3,704.0 | 80% |
|
| Shares Out (Mil) | 157.9 | 107.2 | 71% |
|
| Institutional Ownership | 99.7% | 89.2% | 92% |
|
| Float (Mil) | 156.4 | 83.6 | 69% |
|
| Beta | 1.27 | 1.14 | 73% |
|
| Avg Daily Volume (000s) | 2,953 | 1,029 | 85% |
|
| Price Change (52-week) |
18.6% | 84.8% | 68% |
|
| Growth | TECH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.5% | 7.5% | 39% |
|
| Net Income (5yr) | 5.3% | (12.1%) | 48% |
|
| EPS (5yr) | 5.9% | 2.1% | 40 |
|
| Dividends (5yr) | 0.0% | 0.0% | 62% |
|
| Cash Flow (5yr) | 14.2% | (14.9%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 6 | 10 | |
| Current EPS | $0.483 | $2.028 | $2.312 | |
| Month Ago EPS | $0.481 | $2.037 | $2.313 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.484 | $2.047 | $2.317 | |
| Year/Year Chg | 168.3% | 74.8% | 120.7% | |
| Financials | TECH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,228 | $811 | 52% |
|
| Net Income (TTM) (Mil) | $172 | ($19) | 65% |
|
| EPS (TTM) | $1.100 | ($0.300) | 61% |
|
| Operating Cash Flow (TTM) (Mil) | $338 | $52 | 66% |
|
| Net Cash Flow (TTM) (Mil) | $205 | $3 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $71 | $252 | 41% |
|
| Enterprise Value (Q1) (Mil) | $11,368 | $3,646 | 76% |
|
| Valuation | TECH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.28 | 3.66 | 82% |
|
| P/E | 66.2 | 35.9 | 90% |
|
| Dividend Yield | 0.4% | 0.0% | 62% |
|
| PEG (5yr hist) | 11.2 | 6.6 | 95% |
|
| Ratios | TECH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.2% | 47.8% | 78% |
|
| Net Margin | 14.0% | (3.0%) | 70% |
|
| ROA | 6.7% | (5.4%) | 77% |
|
| ROE | 8.3% | (5.2%) | 51% |
|
| Liabilities to Assets | 17.9% | 41.5% | 11% |
|
| F-Score | 6 | 5 | 67% |
|
Bio-Techne Corporation did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors